...
首页> 外文期刊>International Journal of Nanomedicine >Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma
【24h】

Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma

机译:靶向表柔比星联合塞来昔布脂质体破坏血管生成模拟通道治疗脑胶质瘤

获取原文

摘要

The efficacy of chemotherapy for brain glioma is restricted by the blood–brain barrier (BBB), and surgery or radiotherapy cannot eliminate the glioma cells because of their unique location. Residual brain glioma cells can form vasculogenic mimicry (VM) channels that can cause a recurrence of brain glioma. In the present study, targeting liposomes incorporating epirubicin and celecoxib were prepared and used for the treatment of brain glioma, along with the destruction of their VM channels. Evaluations were performed on the human brain glioma U87MG cells in vitro and on intracranial brain glioma-bearing nude mice. Targeting epirubicin plus celecoxib liposomes in the circulatory blood system were able to be transported across the BBB, and accumulated in the brain glioma region. Then, the liposomes were internalized by brain glioma cells and killed glioma cells by direct cytotoxic injury and the induction of apoptosis. The induction of apoptosis was related to the activation of caspase-8- and -3-signaling pathways, the activation of the proapoptotic protein Bax, and the suppression of the antiapoptotic protein Mcl-1. The destruction of brain glioma VM channels was related to the downregulation of VM channel-forming indictors, which consisted of MMP-2, MMP-9, FAK, VE-Cad, and VEGF. The results demonstrated that the targeting epirubicin plus celecoxib liposomes were able to effectively destroy the glioma VM channels and exhibited significant efficacy in the treatment of intracranial glioma-bearing nude mice. Therefore, targeting epirubicin plus celecoxib liposomes could be a potential nanostructured formulation to treat gliomas and destroy their VM channels.
机译:脑胶质瘤的化学疗法的疗效受到血脑屏障(BBB)的限制,并且手术或放疗由于其独特的位置而无法消除胶质瘤细胞。残留的脑胶质瘤细胞可以形成血管生成模拟(VM)通道,从而导致脑胶质瘤复发。在本研究中,制备了结合了表柔比星和塞来昔布的靶向脂质体,并将其用于治疗脑胶质瘤以及破坏其VM通道。对人脑神经胶质瘤U87MG细胞和颅内脑胶质瘤裸鼠进行了评估。在循环血液系统中靶向表柔比星加塞来昔布脂质体能够跨血脑屏障转运,并积聚在脑神经胶质瘤区域。然后,脂质体被脑神经胶质瘤细胞内化,并通过直接的细胞毒性损伤和细胞凋亡的诱导杀死了神经胶质瘤细胞。凋亡的诱导与caspase-8和-3-信号通路的激活,促凋亡蛋白Bax的激活以及抗凋亡蛋白Mcl-1的抑制有关。脑神经胶质瘤VM通道的破坏与VM通道形成指标的下调有关,该指标由MMP-2,MMP-9,FAK,VE-Cad和VEGF组成。结果表明,靶向表柔比星加塞来昔布脂质体能够有效破坏神经胶质瘤VM通道,并且在治疗颅内神经胶质瘤裸鼠中显示出显着的功效。因此,靶向表柔比星加塞来昔布脂质体可能是治疗神经胶质瘤并破坏其VM通道的潜在纳米结构制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号